The case and the parties
The case is Siemens Medical Solutions USA, Inc. v. Hologic, Inc., No. 1:26-cv-01460 (D. Del.). The complaint was filed on November 13, 2026, with a jury demand. It calls the plaintiff Siemens Healthineers USA and says it is a Delaware corporation with its principal place of business in Malvern, Pennsylvania. It uses "Siemens Healthineers" for the plaintiff and its corporate parent together. It alleges, on information and belief, that Hologic, Inc. is a Delaware corporation with headquarters in Marlborough, Massachusetts.
The complaint says Siemens Healthineers' mammography portfolio includes the MAMMOMAT B.brilliant and MAMMOMAT Revelation systems, which it describes as patented. It says the B.brilliant system is the current-generation system and provides digital mammography and wide-angle three-dimensional breast tomosynthesis, and that the Revelation system provides digital mammography and wide-angle breast tomosynthesis and supports breast-cancer screening, diagnostic imaging, and biopsy.
The asserted patent
The complaint identifies United States Patent No. 8,284,894 as the '894 patent and as the Asserted Patent. It says the patent, titled "Fast Tomosynthesis Scanner Apparatus and CT-Based Method Based on Rotational Step-and-Shoot Image Acquisition Without Focal Spot Motion During Continuous Tube Movement for Use in Cone-Beam Volume CT Mammography Imaging," issued on October 9, 2012, from Application No. 12/933,922, filed March 26, 2009, and that it names Tiemen Poorter as the inventor. The patent states that its term is extended or adjusted under 35 U.S.C. 154(b) by 191 days, and it contains 15 claims.
The complaint alleges that, before issuance, the inventor assigned application 12/933,922 to the patent's original owner, by an assignment recorded at the USPTO at Reel/Frame 025031/0963, and that the original owner owned the patent when it issued. It alleges that the plaintiff's corporate parent acquired the patent from the original owner by an assignment recorded in July 2026 at Reel/Frame 075279/0276, and that the plaintiff then acquired it from its parent by an assignment recorded in October 2026 at Reel/Frame 076217/0096. It alleges that the patent is valid, enforceable, and currently in full force and effect.
The complaint says the patent relates to three-dimensional digital breast tomosynthesis, in which a system acquires a series of low-dose two-dimensional projection images of compressed breast tissue from different angles as an X-ray tube moves along an arc, and reconstructs those images into slices at different depths in the breast. It says a stop-and-shoot procedure, with the tube stationary during each exposure, increases total acquisition time because the tube must stop, image, and move again, and that continuous tube movement also moves the focal spot and may produce serious image blur. It says the patent claims systems and methods that acquire projection images during continuous rotation while the electron-beam focal spot on the anode moves in the opposite direction, so that movement compensates for the distance the tube travels during each acquisition, and that this produces motion-blur-free images in a shorter total acquisition time.
Claims 1 and 10
Claim 1 recites a 3D tomosynthesis scanner apparatus comprising a rotary X-ray tube and a stationary X-ray detector arranged opposite the tube. The apparatus is adapted to acquire a set of 2D projection images during continuous rotational movement of an X-ray tube in an azimuthal direction along an arc of a circular trajectory around an object of interest or a tissue region, and to subject those images to 3D reconstruction. During the acquisition time for each projection image, the electron beam focal spot on the rotary X-ray tube's anode is moved in the opposite direction along the same arc, from a start position to an end position relative to the tube housing, so that the movement compensates for the azimuthal path distance the tube covers during that time. Claim 10 recites a method of operating such an apparatus with those same acquisition, reconstruction, and focal-spot compensation steps.
The count
Count 1 alleges, upon information and belief, that Hologic has infringed and continues to infringe at least claims 1 and 10, either literally or under the doctrine of equivalents, under 35 U.S.C. 271(a), (b), and (c), by making, using, offering to sell, and/or selling in the United States, and/or importing into the United States, the accused products. Paragraph 1 defines the accused products as Hologic's mammography systems, including the Envision Mammography Platform. Within the count, the complaint says Hologic makes and assembles the final accused product in Newark, Delaware, and alleges infringing use of the Envision system during pre-sale demonstrations and product unveilings, including a December 2024 unveiling of the Envision Mammography Platform at a radiology society's annual meeting. It alleges, on information and belief, that the infringing use further includes design-verification, validation, quality-control, and other internal and clinical testing of the Envision system.
The complaint alleges that the accused products infringe at least claims 1 and 10, as illustrated in an exemplary claim chart attached as Exhibit 3. It says that claim chart relies in part on the technical description of the Envision Mammography Platform in an October 24, 2024 letter from the USPTO to the FDA regarding Hologic's request for patent-term extension of U.S. Patent No. 8,457,282, attached as Exhibit 4.
The complaint alleges that Hologic has had actual knowledge of the '894 patent since before this action and that, despite having knowledge of its infringement, Hologic continues to intentionally and willfully infringe at least claims 1 and 10, or at the very least to act with willful blindness and/or a reckless disregard of the plaintiff's patent rights. It says Siemens Healthineers sent Hologic an email on August 13, 2026, identifying the patent. It says the '894 patent family played a significant role as prior art in a European Patent Office opposition proceeding initiated by Hologic on May 14, 2019 (appeal T 1762/21), and that the family was identified in Siemens Healthineers' Statement of Defense and Counterclaim for Revocation filed on March 26, 2025, in Unified Patent Court proceeding UPC_CFI_758/2024 against Hologic. The complaint says this shows deep knowledge and understanding of the patent before the complaint was filed. It alleges that willful infringement entitles the plaintiff to treble damages and attorneys' fees and costs, with prejudgment interest, under 35 U.S.C. 284 and 285.
The complaint alleges, on information and belief, that Hologic actively, knowingly, and intentionally induces infringement of the asserted claims by encouraging others, including hospitals, imaging centers, radiologists, and technologists, to make, use, offer to sell, and/or sell the accused products in the United States, with the specific intent to encourage that infringement. It points to designing, making, selling, offering to sell, importing, marketing, advertising, and promoting the products; marketing, promotional, educational, and other product literature; instructional and promotional videos; and training, medical education, and customer support. It alleges, on information and belief, contributory infringement by offering to sell, selling, or importing components that are especially made or adapted for an infringement and are not a staple article or commodity of commerce suitable for substantial non-infringing use. The example it gives is the moving-focal-spot acquisition functionality of the accused products.
Jurisdiction, venue, and relief
The complaint alleges subject matter jurisdiction under 28 U.S.C. 1331 and 1338, and says the action arises under the patent laws, 35 U.S.C. 100 and the sections that follow, including 35 U.S.C. 271 and 281 through 285. It alleges personal jurisdiction because Hologic is a Delaware corporation with a registered office in Delaware, and says Hologic has designated a registered agent in Dover, Delaware. It alleges specific jurisdiction based on contacts with Delaware, including manufacture and sale of products used in Delaware. It states that Hologic manufactures the Envision Mammography Platform in Newark, Delaware, where it says Hologic conducts its U.S. Breast Health capital equipment manufacturing operations. It alleges venue under 28 U.S.C. 1391 and 1400 because Hologic resides in Delaware, its state of incorporation, citing TC Heartland LLC v. Kraft Foods Grp. Brands LLC, 581 U.S. 258, 262 (2017). It also alleges venue under 28 U.S.C. 1400(b), stating that Hologic has committed acts of infringement in the District, including by making the accused products in Newark, Delaware, and has a regular and established place of business in the District at that manufacturing facility.
The complaint alleges that Hologic will continue to infringe unless enjoined, and that the infringement has caused and will continue to cause irreparable harm unless enjoined. The prayer asks for a judgment declaring that Hologic has infringed the asserted patent directly, contributorily, and by inducement; a judgment declaring that the infringement is willful pursuant to 35 U.S.C. 284; an injunction under 35 U.S.C. 283 against Hologic and its officers, directors, agents, servants, employees, and attorneys, and persons in active concert or participation with them, from infringing the asserted patent by commercial manufacture, use, offer to sell, or sale within the United States, or importation into the United States, of any product covered by the patent, for the full term or any additional period of exclusivity to which the plaintiff or the patent is or becomes entitled, and from inducing or contributing to those activities; damages sufficient to compensate for the infringement, with prejudgment and post-judgment interest and costs; an accounting for the damages resulting from infringement, with interest and costs, and all other damages permitted by 35 U.S.C. 284, including an accounting for infringing acts not presented at trial and an award of additional damages for those acts; a judgment that the case is exceptional, with expenses, costs, and attorneys' fees under 35 U.S.C. 285, Rule 54(d) of the Federal Rules of Civil Procedure, and other applicable statutes, rules, and common law; taxation of allowable costs; and other relief the court deems just and proper. The complaint demands a jury trial.
What to watch next
Watch for Hologic's answer or a Rule 12 motion. The case can end at any time, including by settlement or voluntary dismissal.